141 related articles for article (PubMed ID: 30589642)
1. Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors.
Mantovani G; Treppiedi D; Giardino E; Catalano R; Mangili F; Vercesi P; Arosio M; Spada A; Peverelli E
Endocr Relat Cancer; 2019 Feb; 26(2):R95-R108. PubMed ID: 30589642
[TBL] [Abstract][Full Text] [Related]
2. A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment.
Peverelli E; Giardino E; Treppiedi D; Catalano R; Mangili F; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
Int J Cancer; 2018 May; 142(9):1842-1852. PubMed ID: 29226331
[TBL] [Abstract][Full Text] [Related]
3. A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation.
Mangili F; Treppiedi D; Catalano R; Marra G; Di Muro G; Spada A; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2020; 11():611752. PubMed ID: 33664708
[TBL] [Abstract][Full Text] [Related]
4. Filamin A in somatostatin and dopamine receptor regulation in pituitary and the role of cAMP/PKA dependent phosphorylation.
Peverelli E; Giardino E; Vitali E; Treppiedi D; Lania AG; Mantovani G
Horm Metab Res; 2014 Nov; 46(12):845-53. PubMed ID: 25068602
[TBL] [Abstract][Full Text] [Related]
5. cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells.
Peverelli E; Giardino E; Mangili F; Treppiedi D; Catalano R; Ferrante E; Sala E; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
Cancer Lett; 2018 Oct; 435():101-109. PubMed ID: 30098401
[TBL] [Abstract][Full Text] [Related]
6. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
[TBL] [Abstract][Full Text] [Related]
7. Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement.
Peverelli E; Treppiedi D; Giardino E; Vitali E; Lania AG; Mantovani G
Front Endocrinol (Lausanne); 2015; 6():187. PubMed ID: 26733942
[TBL] [Abstract][Full Text] [Related]
8. Single-Molecule Microscopy Reveals Dynamic FLNA Interactions Governing SSTR2 Clustering and Internalization.
Treppiedi D; Jobin ML; Peverelli E; Giardino E; Sungkaworn T; Zabel U; Arosio M; Spada A; Mantovani G; Calebiro D
Endocrinology; 2018 Aug; 159(8):2953-2965. PubMed ID: 29931263
[TBL] [Abstract][Full Text] [Related]
9. Dopamine receptor type 2 (DRD2) inhibits migration and invasion of human tumorous pituitary cells through ROCK-mediated cofilin inactivation.
Peverelli E; Giardino E; Treppiedi D; Locatelli M; Vaira V; Ferrero S; Bosari S; Lania AG; Spada A; Mantovani G
Cancer Lett; 2016 Oct; 381(2):279-86. PubMed ID: 27519461
[TBL] [Abstract][Full Text] [Related]
10. [New medical treatments in pituitary adenomas].
Drutel A; Caron P; Archambeaud F
Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
[TBL] [Abstract][Full Text] [Related]
11. Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST
Treppiedi D; Marra G; Di Muro G; Catalano R; Mangili F; Esposito E; Calebiro D; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2022; 13():892668. PubMed ID: 35992099
[TBL] [Abstract][Full Text] [Related]
12. Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs.
Peverelli E; Mantovani G; Vitali E; Elli FM; Olgiati L; Ferrero S; Laws ER; Della Mina P; Villa A; Beck-Peccoz P; Spada A; Lania AG
J Clin Endocrinol Metab; 2012 Mar; 97(3):967-77. PubMed ID: 22259062
[TBL] [Abstract][Full Text] [Related]
13. Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor/stem-like cells isolated from nonfunctioning pituitary tumors.
Peverelli E; Giardino E; Treppiedi D; Meregalli M; Belicchi M; Vaira V; Corbetta S; Verdelli C; Verrua E; Serban AL; Locatelli M; Carrabba G; Gaudenzi G; Malchiodi E; Cassinelli L; Lania AG; Ferrero S; Bosari S; Vitale G; Torrente Y; Spada A; Mantovani G
Int J Cancer; 2017 Apr; 140(8):1870-1880. PubMed ID: 28120505
[TBL] [Abstract][Full Text] [Related]
14. Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells.
Peverelli E; Giardino E; Treppiedi D; Vitali E; Cambiaghi V; Locatelli M; Lasio GB; Spada A; Lania AG; Mantovani G
Endocrinology; 2014 Aug; 155(8):2932-41. PubMed ID: 24828612
[TBL] [Abstract][Full Text] [Related]
15. Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours.
Vitali E; Cambiaghi V; Zerbi A; Carnaghi C; Colombo P; Peverelli E; Spada A; Mantovani G; Lania AG
Endocr Relat Cancer; 2016 Mar; 23(3):181-90. PubMed ID: 26733502
[TBL] [Abstract][Full Text] [Related]
16. Filamin A Orchestrates Cytoskeletal Structure, Cell Migration and Stem Cell Characteristics in Human Seminoma TCam-2 Cells.
Welter H; Herrmann C; Fröhlich T; Flenkenthaler F; Eubler K; Schorle H; Nettersheim D; Mayerhofer A; Müller-Taubenberger A
Cells; 2020 Nov; 9(12):. PubMed ID: 33266100
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms involved in somatostatin receptor regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations.
Peverelli E; Treppiedi D; Mantovani G
Endocr Oncol; 2022 Jan; 2(1):R24-R30. PubMed ID: 37435448
[TBL] [Abstract][Full Text] [Related]
18. The function and pathogenic mechanism of filamin A.
Zhou J; Kang X; An H; Lv Y; Liu X
Gene; 2021 Jun; 784():145575. PubMed ID: 33737122
[TBL] [Abstract][Full Text] [Related]
19. [Filamin A as a mediator of alterations in cancer cells].
Wieczorek K; Niewiarowska J
Postepy Biochem; 2014; 60(1):77-83. PubMed ID: 25033545
[TBL] [Abstract][Full Text] [Related]
20. FLNA expression modulates pathological markers of pituitary neuroendocrine tumours.
Toledo J; Perez PA; Zanetti M; Díaz-Torga G; Mukdsi JH; Gutierrez S
J Endocrinol; 2024 Jan; 260(1):. PubMed ID: 37855268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
